ArticleAdvances in hematology2010
Red blood cell transfusion independence following the initiation of iron chelation therapy in myelodysplastic syndrome.
Article in Advances in hematology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Serum or plasma ferritin concentration as an index of iron deficiency and overload.The Cochrane database of systematic reviews · 2021Pooled it
- Deferasirox for managing iron overload in people with myelodysplastic syndrome.The Cochrane database of systematic reviews · 2014Pooled it
- Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes.Haematologica · 2012Trial
- A correlation of ineffective erythropoiesis and dysregulated signaling pathways in myelodysplastic syndromes/neoplasms.Experimental hematology & oncology · 2025Article
- Low-risk MDS-A spotlight on precision medicine forHemaSphere · 2025Review
- Treatment of Anemia in Lower-Risk Myelodysplastic Syndrome.Current treatment options in oncology · 2024Review
- Iron overload induces dysplastic erythropoiesis and features of myelodysplasia in Nrf2-deficient mice.Leukemia · 2024Article
- Iron chelation improves ineffective erythropoiesis and iron overload in myelodysplastic syndrome mice.eLife · 2023Article
- Review
- Deferasirox drives ROS-mediated differentiation and induces interferon-stimulated gene expression in human healthy haematopoietic stem/progenitor cells and in leukemia cells.Stem cell research & therapy · 2019Article
- Management of anemia in low-risk myelodysplastic syndromes treated with erythropoiesis-stimulating agents newer and older agents.Medical oncology (Northwood, London, England) · 2018Review
- Reactive oxygen species levels control NF-κB activation by low dose deferasirox in erythroid progenitors of low risk myelodysplastic syndromes.Oncotarget · 2017Article
- Myelodysplastic Syndromes and Iron Chelation Therapy.Mediterranean journal of hematology and infectious diseases · 2017Review
- A case of transfusion independence in a patient with myelodysplastic syndrome using deferasirox, sustained for two years after stopping therapy.Current oncology (Toronto, Ont.) · 2015Article
- Cancer cells with irons in the fire.Free radical biology & medicine · 2015Review
- Durable Red Blood Cell Transfusion Independence in a Patient with an MDS/MPN Overlap Syndrome Following Discontinuation of Iron Chelation Therapy.Case reports in hematology · 2015Article
- Impact of iron overload and potential benefit from iron chelation in low-risk myelodysplastic syndrome.Blood · 2014Review
- Physiology and pathophysiology of iron in hemoglobin-associated diseases.Free radical biology & medicine · 2014Review
- Optimizing therapy for iron overload in the myelodysplastic syndromes: recent developments.Drugs · 2011Review
- Crosstalk between Erythropoiesis and Iron Metabolism.Advances in hematology · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Iron chelation therapy is often used to treat iron overload in patients requiring transfusion of red blood cells (RBC). A 76-year-old man with MDS type refractory cytopenia with multilineage dysplasia, intermediate-1 IPSS risk, was referred when he became transfusion dependent. He declined infusional chelation but subsequently accepted oral therapy. Following the initiation of chelation, RBC transfusion requirement ceased and he remained transfusion independent over 40 months later. Over the same time course, ferritin levels decreased but did not normalize. There have been eighteen other MDS patients reported showing improvement in hemoglobin level with iron chelation; nine became transfusion independent, nine had decreased transfusion requirements, and some showed improved trilineage myelopoiesis. The clinical features of these patients are summarized and possible mechanisms for such an effect of iron chelation on cytopenias are discussed.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.